Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspecs Group Regulatory News (SPEC)

Share Price Information for Inspecs Group (SPEC)

Share Price is delayed by 15 minutes
Get Live Data
84.50    0.00 (0.00%)
Bid:
82.00
Ask:
87.00
Spread: 5.00 (6.098%)
Market Cap: £85.91m
SPEC Live PriceLast checked at - London Stock Exchange

Intraday Inspecs Group Share Chart

Half Year Trading Update

31 Jul 2025 07:00

RNS Number : 2825T
Inspecs Group PLC
31 July 2025
Β 

31 July 2025

Β 

Inspecs Group plc

("INSPECS" or "the Group")

Β 

Half Year Trading Update

Β 

Inspecs Group plc, a leading designer, manufacturer and distributor of eyewear (sunglasses, optical frames, lenses and low vision products) provides a trading update for the six months ended 30 June 2025, ahead of reporting its interim results on 18 September 2025.

Β 

Trading update

As reported on 3 June 2025, Group sales to the end of May were impacted by the uncertainty surrounding US tariffs. This continued throughout June and as a result, Group revenue for H1 2025 was Β£100.0 million, a 2.9% decrease compared to H1 2024. On a constant currency basis1, revenue for H1 2025 was Β£101.7 million, a 1.3% decrease compared to H1 2024. The Board expects to report Underlying EBITDA for H1 2025 of circa Β£8.2m (H1 2024: Β£10.1m) on a like-for-like basis2.

Β 

We have a strong order book for H2 2025 and, once trade negotiations are settled, we expect our businesses affected by the tariffs to return to growth in the second half of the year. We have also secured the listing of key brands into the European and US markets. Further to the update provided on 3 June 2025, the operational efficiency and cost-saving plans, including the consolidation of our US, German and Swedish operations, are expected to yield additional savings in H2. As a result, we now expect full year revenue and Underlying EBITDA to be in line with 2024 on a like-for-like basis2.

Β 

Norville strategic review

INSPECS has completed the strategic review of its lens manufacturing subsidiary, Norville (20/20) Limited ("Norville"). As a result, the Group is now actively engaged in discussions with a number of strategically aligned buyers about a sale of the business as a going concern. Meanwhile, monthly losses have been materially reduced in Q2.

Β 

Non-Executive Chair recruitment

Good progress has been made in the process of recruiting a new Independent Non-Executive Chair. An excellent candidate has been identified and, subject to satisfactory completion of normal due diligence procedures, an announcement of the appointment is expected to be made shortly.

Β 

Β 

1. Constant exchange rates: figures at constant exchange rates have been calculated using the average exchange rates in effect for the corresponding period in the relevant comparative year.

2. The Group will show the financial performance of Norville (20/20) Limited separately in its interim results as a discontinued operation. However, in this announcement figures are given on a like-for-like basis (i.e. including Norville).

Β 

Β 

For further information please contact:

Β 

Inspecs Group plc

Richard Peck (CEO)

Chris Kay (CFO)

Β 

Β 

via FTI Consulting

Tel: +44 (0) 20 3727 1000

Peel Hunt (Nominated Adviser and Broker)

George Sellar

Andrew Clark

Β 

Β 

Tel: +44 (0) 20 7418 8900

FTI Consulting (Financial PR)

Alex Beagley

Harriet Jackson

Amy Goldup

Tel: +44 (0) 20 3727 1000

Β 

Β 

About Inspecs Group plc

INSPECS is a leading provider of eyewear solutions to the global eyewear market. The Group produces a broad range of eyewear frames, low vision aids and lenses, covering optical, sunglasses and safety, which are either "Branded" (under licence or under the Group's own proprietary brands), or "OEM" (unbranded or private label on behalf of retail customers).

Β 

INSPECS is building a global eyewear business through its vertically integrated business model. Its continued growth is underpinned by increasing the penetration of its own-brand portfolio, worldwide distribution, growing retail presence, maximising group synergies and its global network, expanding its manufacturing capacity and scaling the research and development department as it develops new and innovative eyewear products. The Group has operations across the globe: with offices and subsidiaries in the UK, Germany, Portugal, Scandinavia, the US and China (including Hong Kong, Macau and Shenzhen), and manufacturing facilities in Vietnam, China, the UK and Italy.

Β 

INSPECS customers are global optical and non-optical retailers, global distributors and independent opticians. Its distribution network covers over 80 countries and reaches approximately 75,000 points of sale.

Β 

More information is available at: https://inspecs.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTPKKBDFBKDQON
Date   Source Headline
19th May 20269:14 amRNSHolding(s) in Company
19th May 20267:00 amRNSBoard Changes
18th May 20267:00 amRNSBoard Changes
18th May 20267:00 amRNSOffer Closed
13th May 20267:00 amRNSFinal Results for the year ended 31 December 2025
1st May 20265:00 pmRNSClosure of the Offer
24th Mar 20267:00 amRNSAcceptance Level Update
18th Mar 202611:42 amRNSHolding(s) in Company
17th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
17th Mar 20269:16 amRNSForm 8.3 - INSPECS GROUP PLC
17th Mar 20267:45 amRNSDisclosure Table
17th Mar 20267:45 amRNSDisclosure Table
17th Mar 20267:00 amRNSDay 21 Acceptance Level Update
17th Mar 20267:00 amRNSDay 21 Acceptance Level Update
16th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
16th Mar 20268:44 amRNSForm 8.3 - INSPECS GROUP PLC
13th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
13th Mar 20267:00 amRNSOffer Declared Unconditional
13th Mar 20267:00 amRNSOffer Declared Unconditional
11th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
10th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
10th Mar 202610:40 amRNSHolding(s) in Company
10th Mar 20268:54 amRNSForm 8.3 - INSPECS GROUP PLC
9th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
9th Mar 20269:17 amRNSForm 8.3 - INSPECS GROUP PLC
6th Mar 20261:02 pmRNSForm 8.3 - Inspecs Group Plc
6th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
6th Mar 20269:26 amRNSForm 8.3 - INSPECS GROUP PLC
5th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
5th Mar 20269:32 amRNSForm 8.3 - INSPECS GROUP PLC
4th Mar 20265:00 pmRNSSatisfaction of NSIA Condition
4th Mar 20261:20 pmRNSAIM Rules Confirmation
4th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
4th Mar 20269:30 amRNSForm 8.3 - INSPECS GROUP PLC
4th Mar 20268:34 amBUSForm 8.3 - Inspecs Group Plc
3rd Mar 20265:22 pmRNSHolding(s) in Company
3rd Mar 20264:38 pmRNSForm 8.3 - Inspecs Group PLC
3rd Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
2nd Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
27th Feb 20261:09 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
26th Feb 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
25th Feb 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
25th Feb 20269:10 amGNWForm 8.3 - Inspecs Group Plc
23rd Feb 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
23rd Feb 202611:46 amRNSHolding(s) in Company
23rd Feb 202611:30 amRNSPublication of the Offer Document
20th Feb 20266:32 pmRNSSwitch to a Takeover Offer
20th Feb 20266:01 pmRNSSwitch to a Takover Offer
20th Feb 20264:30 pmRNSForm 8.3 - INSPECS GROUP PLC
20th Feb 20264:01 pmBUSForm 8.3

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.